American Shared Hospital Services (NYSE: AMS) – Q1 2026 Earnings
American Shared Hospital Services (NYSE: AMS) – Q1 2026 Earnings
Press release and earnings call link
Section 1: Short Tear Sheeet
American Shared Hospital Services (AMS) provides advanced cancer treatment equipment and services, including Gamma Knife radiosurgery, proton beam radiation therapy (PBRT), linear accelerator radiation therapy (LINAC), and direct patient care services through radiation therapy centers. The company historically relied more on medical equipment leasing, but is now shifting toward a more direct patient care model, where AMS participates more directly in center utilization, reimbursement, and operating performance. In Q1 2026, AMS showed a turnaround/growth profile: revenue rose 15.9% to $7.1 million, direct patient services revenue rose 30.2%, gross margin improved to 18.2%, and adjusted EBITDA increased 18.4%, although the company still reported a GAAP net loss. The main near-term themes are higher treatment volumes, margin expansion from utilization, improved execution under interim CEO Craig Tagawa, capital structure repair, and long-term expansion in Rhode Island and Mexico.
Quarterly Results
Earnings Release Date: May 14, 2026
Stock Price: $1.68
Market Cap: $11.3 million
Q1 2026 sales of $7.1 million vs $6.1 million in the prior year
Q1 2026 GAAP Diluted EPS of $(0.09) vs $(0.10) in the prior year
Quick Takeaway
American Shared Hospital Services is in a turnaround/growth transition phase, shifting from a legacy equipment leasing model toward a larger direct patient care platform. The strongest positives are higher treatment volumes, 30.2% growth in direct patient services, improved gross margin, and positive Q2 volume commentary. The main risks are continued GAAP losses, higher fixed costs from newer facilities, unresolved lender discussions, and the need to fund long-term growth projects.
Press Release vs Call Transcript Comparison
The press release gives a clean operating improvement story, but the call is more important for understanding what could change investor perception. The most valuable call-only items are the two-year contract extension, the Rhode Island project timelines, the Guadalajara expected launch timing, and the bank discussion details. These are the kinds of disclosures that can shift how investors think about revenue durability, project optionality, and balance sheet risk.
The biggest positive is that the direct patient care strategy appears to be gaining traction. Revenue growth is not coming from one accounting item or one-time event; it is being driven by higher patient volumes across Rhode Island, Puebla, Orlando PBRT, and international Gamma Knife centers. The biggest risk is that this model requires sustained utilization growth because the direct care footprint carries higher staffing, facility, and maintenance costs.
Investor Underappreciation Signals
✅Contract Extension De-Risking — The call disclosed that a potentially expiring contract was extended for two years, which investors may overlook because the press release mainly discusses prior contract expiration as a headwind.
✅Utilization-Driven Margin Expansion — Higher treatment volumes are beginning to improve gross margin and narrow operating losses, and investors may miss this because AMS is still reporting a GAAP net loss.
✅Direct Patient Care Mix Shift — The growth is coming from the direct patient services segment, which gives AMS more control over revenue streams, and investors may underappreciate this because the legacy leasing business still dominates how the company is perceived.
✅Puebla Reimbursement Tailwind — Puebla is benefiting from improved reimbursement dynamics and operational ramp-up, and investors may overlook it because it is grouped into the broader direct patient care revenue line.
✅Rhode Island Long-Term Pipeline — Bristol and Johnston are not near-term revenue contributors, but they give AMS a defined multi-year expansion path that may not be reflected in current valuation.
✅Guadalajara Late-Year Launch — The call added that Guadalajara is expected to begin operations late this year, which could become an international growth catalyst not emphasized in the press release.
✅Liquidity Improvement With Repatriation Angle — Cash moved back above $5 million and some international cash was repatriated, which could matter more than investors realize if it helps resolve bank compliance concerns.
✅Leadership Continuity Under Tagawa — The CEO transition may look risky at first glance, but Tagawa’s 35-year operating history with AMS could support continuity during a critical execution phase.
Section 2: Supplementary Information
Positive Insights
Negative Insights
Tariff Risk
The transcript does not mention U.S. tariffs, trade policy, tariff-related supply chain disruptions, or tariff-driven pricing actions. There is no discussion of shifting production, renegotiating supplier contracts, changing pricing, or protecting margins from tariff exposure.
The closest related issue is higher maintenance expense from LINAC systems coming out of warranty and increased PBRT maintenance contract costs, but management did not link those cost increases to tariffs. Based only on the transcript, tariff risk does not appear to be a stated near-term issue for AMS.
Hot Stock Trends Analysis
Previous Earnings Call
Quarter-over-quarter comparison
In Q4 2025, AMS was still explaining the cost of its strategic transition. The company had shifted toward direct patient care, but the benefits were being obscured by lost leasing contracts, lower proton therapy volumes, higher operating costs, lender covenant issues, and a frustrated shareholder base. Management’s message was essentially: 2025 was painful, but the company made the investments needed to build a better platform.By Q1 2026, the narrative had shifted toward early validation. Direct patient care growth, higher utilization, improved gross margin, and adjusted EBITDA growth suggested the new model was beginning to work. The story is not fully de-risked because AMS remains loss-making, lender negotiations are still unresolved, and major expansion projects are long-dated, but the company moved from a transition-year defense to a clearer turnaround narrative built around volume growth, margin recovery, and direct patient care scale.
Year-over-year comparison
In Q1 2025, AMS was selling investors on the promise of its transformation. The company had strong revenue growth from Rhode Island and Puebla, but lower procedure volumes, leasing contract expirations, and weaker adjusted EBITDA showed that the new direct patient care model was still early and uneven. Management’s message was that short-term volatility should be expected, but the long-term growth platform was being built.
By Q1 2026, that same strategy had more evidence behind it. Direct patient services continued to grow, higher utilization improved gross margin, adjusted EBITDA increased, and operating loss narrowed. The story improved from “growth investment phase” to “early operating leverage phase,” but it also gained new risks: lower cash, lender negotiations, higher maintenance costs, and a CEO transition. Overall, AMS’s narrative evolved from an ambitious transition story into a more credible turnaround story, with the next test being whether improved utilization can overcome balance sheet pressure and produce sustained profitability.